SCHEMBL4175718

SCHEMBL4175718

C[S+]([O-])c1ccc(C2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.56
GPR119 Q8TDV5 6/20 0.53
DDB1 Q16531 1/20 0.50
CRBN Q96SW2 1/20 0.50
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
THRB P10828 1/20 0.49
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
PDE4B Q07343 1/20 0.46
P2RY14 Q15391 1/20 0.45
ALDH1A1 P00352 2/20 0.44
RET P07949 1/20 0.44
STS P08842 2/20 0.44
NPC1 O15118 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12813451 0.86 GPR119 (0.75) NAMPTGPR119KDM4E
SCHEMBL12965147 0.86 GPR119 (0.75) NAMPTGPR119KDM4E
SCHEMBL12813448 0.86 GPR119 (0.75) NAMPTGPR119KDM4E
SCHEMBL12117456 0.82 GPR119 (0.65) NAMPTGPR119DDB1CRBNMAPT
SCHEMBL3854559 0.82 NAMPT (0.61) NAMPTGPR119DDB1CRBNMAPT
SCHEMBL25666788 0.82 NAMPT (0.58) NAMPTGPR119DDB1CRBNMAPT
SCHEMBL3485674 0.81 GPR119 (0.72) GPR119MAPTPTPN2PTPN1PTPN6
SCHEMBL12321681 0.81 NAMPT (0.60) NAMPTGPR119DDB1CRBNMAPT
SCHEMBL270733 0.81 NAMPT (0.60) NAMPTGPR119DDB1CRBNMAPT
SCHEMBL2594236 0.81 NAMPT (0.60) NAMPTGPR119DDB1CRBNMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 US disclosed
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 US disclosed
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 US disclosed
WO-2008075070-A1 SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS ASTRAZENECA AB (SE) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105305-A1 Therapeutic Agents - 550 FABP4, GPR119, FASN NAMPT 211/4885GPR119 2/4885DDB1 4270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.